Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 21;14(5):472.
doi: 10.3390/diagnostics14050472.

Association of Blood NK Cell Phenotype with the Severity of Liver Fibrosis in Patients with Chronic Viral Hepatitis C with Genotype 1 or 3

Affiliations

Association of Blood NK Cell Phenotype with the Severity of Liver Fibrosis in Patients with Chronic Viral Hepatitis C with Genotype 1 or 3

Vladislav Vladimirovich Tsukanov et al. Diagnostics (Basel). .

Abstract

Background: NK cells phenotype and functional state in different genotypes of chronic viral hepatitis C (CVHC), depending on liver fibrosis severity, have not been sufficiently studied, which limits the possibilities for the development of pathology therapy.

Methods: The CVHC diagnosis was based on the EASL recommendations (2018). Clinical examination with liver elastometry was performed in 297 patients with genotype 1 and in 231 patients with genotype 3 CVHC. The blood NK cells phenotype was determined by flow cytometry in 74 individuals with genotype 1 and in 69 individuals with genotype 3 CVHC.

Results: The frequency of METAVIR liver fibrosis stages F3-F4 was 32.5% in individuals with genotype 3, and 20.5% in individuals with genotype 1 CVHC (p = 0.003). In patients with both genotype 1 and genotype 3 CVHC, a decrease in the total number of blood NK cells, CD56brightCD16+ NK cells and an increase in the proportion of CD56dimCD16+ NK cells, CD94+ and CD38 + CD73+ NK cells were registered in patients with fibrosis stage F3-F4 by METAVIR in comparison with persons with METAVIR fibrosis stage F0-F1.

Conclusions: In patients with both genotype 1 and genotype 3 CVHC, an imbalance in the ratio between cytokine-producing and cytotoxic NK cells and an increase in the content of NK cells that express inhibitory molecules were determined in patients with severe liver fibrosis.

Keywords: NK cells; liver fibrosis; phenotype; receptor expression; subsets; viral hepatitis C.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Example of tactics for gating NK cells according to panel 1. The color visualizes the distribution of cells expressing the following receptors: CD3—pink, CD16—green, CD56—red. Cells in the E3 gate that do not express CD3, CD16, and CD56 markers are shown in gray.
Figure 2
Figure 2
Subset composition of NK cells in patients with chronic hepatitis C (HCV genotype 1). Horizontal bars depict the group medians and quartile ranges (Me (IQR)) of the quantitative data (% NK cell subsets within total lymphocytes population). Statistical analysis was performed with the Mann–Whitney U test. Description of p value mark (compared to control): *—p value ≤ 0.05, **—p value ≤ 0.01, ***—p value ≤ 0.001. Subfigures show the distribution of NK cell subsets in groups of fibrosi of varying severity and control: (A)—total NK cells (CD3CD56+), (B)—CD56brightCD16, (C)—CD56brightCD16+, (D)—CD56dimCD16, (E)—CD56dimCD16+, (F)—CD56brightCD94, (G)—CD56brightCD94+, (H)—CD56dimCD94, (I)—CD56dimCD94+.
Figure 3
Figure 3
Subset composition of NK cells in patients with chronic hepatitis C (HCV genotype 3). Horizontal bars depict the group medians and quartile ranges (Me (IQR)) of the quantitative data (% NK cell subsets within total lymphocytes population). Statistical analysis was performed with the Mann–Whitney U test. Description of p value mark (compared to control): **—p value ≤ 0.01, ***—p value ≤ 0.001. Subfigures show the distribution of NK cell subsets in groups of fibrosi of varying severity and control: (A)—total NK cells (CD3CD56+), (B)—CD56brightCD16, (C)—CD56brightCD16+, (D)—CD56dimCD16, (E)—CD56dimCD16+, (F)—CD56brightCD94, (G)—CD56brightCD94+, (H)—CD56dimCD94, (I)—CD56dimCD94+.
Figure 4
Figure 4
Dynamics of cytokine-producing and cytotoxic NK cells in CVHC patients with genotypes 1 and 2 depending on liver fibrosis. P1-4 is comparison reliability of control persons and CVHC patients with METAVIR fibrosis stage F3-F4.

Similar articles

References

    1. Bartenschlager R., Baumert T.F., Bukh J., Houghton M., Lemon S.M., Lindenbach B.D., Lohmann V., Moradpour D., Pietschmann T., Rice C.M., et al. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Res. 2018;248:53–62. doi: 10.1016/j.virusres.2018.02.016. - DOI - PubMed
    1. de Oliveria Andrade L.J., D’Oliveira A., Melo R.C., De Souza E.C., Costa Silva C.A., Paraná R. Association between hepatitis C and hepatocellular carcinoma. J. Glob. Infect. Dis. 2009;1:33–37. doi: 10.4103/0974-777X.52979. - DOI - PMC - PubMed
    1. Hayes C.N., Imamura M., Tanaka J., Chayama K. Road to elimination of HCV: Clinical challenges in HCV management. Liver Int. 2022;42:1935–1944. doi: 10.1111/liv.15150. - DOI - PubMed
    1. Isakov V., Nikityuk D. Elimination of HCV in Russia: Barriers and Perspective. Viruses. 2022;14:790. doi: 10.3390/v14040790. - DOI - PMC - PubMed
    1. Pimenov N., Kostyushev D., Komarova S., Fomicheva A., Urtikov A., Belaia O., Umbetova K., Darvina O., Tsapkova N., Chulanov V. Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia. Pathogens. 2022;11:1482. doi: 10.3390/pathogens11121482. - DOI - PMC - PubMed